Literature DB >> 24719019

Treatment of the neck in carcinoma of the parotid gland.

Safina Ali1, Frank L Palmer, Monica DiLorenzo, Jatin P Shah, Snehal G Patel, Ian Ganly.   

Abstract

PURPOSE: To review our experience in the treatment of the neck in patients with carcinoma of the parotid gland.
METHODS: A total of 263 patients were stratified into 3 groups: no neck dissection (NoND), elective neck dissection (END), and therapeutic neck dissection (TND). Clinicopathological characteristics of END and TND versus NoND were compared by Chi square test. Pathological positivity of each neck level was quantified. Neck recurrence-free survival was determined by Kaplan-Meier statistics.
RESULTS: There were 232 cN0 and 31 cN+ patients. Of the cN0 patients, 74 had END. All cN+ patients had TND. Of the END group, occult neck metastases were detected in 26 (35 %) patients. The percentage of positivity was 6.7, 28.3, 21.3, 10.8, and 6.7 % for levels I to V, respectively. Compared to the NoND group, the END group was more likely to be over 60 years old, to have cT3T4 disease, and to have disease with more aggressive histology. Of the TND group, pathological positivity was found in 87 %. The percentage of positivity was 51.6, 77, 73, 53, and 40 % for levels I to V, respectively. Patients who had disease-positive necks had a poorer neck recurrence-free survival of 84.8 %.
CONCLUSIONS: In patients with cN0 disease, observation of the neck is safe in those who are under 60 years of age with clinical T1 or T2 tumors and who have low-grade histology. END should be carried out in patients with cT3T4 disease or high-grade histology and should involve levels II to IV at a minimum. Patients with cN+ disease commonly have all neck levels involved and therefore should be managed with comprehensive neck dissection.

Entities:  

Mesh:

Year:  2014        PMID: 24719019     DOI: 10.1245/s10434-014-3681-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  9 in total

1.  Patterns of lymph node metastasis and the management of neck dissection for parotid carcinomas: a single-institute experience.

Authors:  Tsuyoshi Jinnin; Ryo Kawata; Masaaki Higashino; Shuji Nishikawa; Tetsuya Terada; Shin-Ichi Haginomori
Journal:  Int J Clin Oncol       Date:  2019-02-09       Impact factor: 3.402

Review 2.  [Surgery for parotid gland cancer-controversial and proven aspects].

Authors:  Konstantinos Mantsopoulos; Heinrich Iro
Journal:  HNO       Date:  2022-05-17       Impact factor: 1.284

3.  Development of a novel salivary gland cancer lymph node staging system.

Authors:  Katri Aro; Allen S Ho; Michael Luu; Sungjin Kim; Mourad Tighiouart; Jon Mallen-St Clair; Emi J Yoshida; Stephen L Shiao; Ilmo Leivo; Zachary S Zumsteg
Journal:  Cancer       Date:  2018-05-09       Impact factor: 6.860

Review 4.  Current Issues in Treatment of Parotid Gland Cancer and Advanced Surgical Technique of Robotic Parotidectomy.

Authors:  Young Min Park; Yoon Woo Koh
Journal:  Curr Oncol Rep       Date:  2022-01-21       Impact factor: 5.075

5.  Radiotherapy as salvage treatment of salivary duct carcinoma in major salivary glands without radical operations.

Authors:  Lu Di; Kai Qian; Chengrun Du; Chunying Shen; Ruiping Zhai; Xiayun He; Xiaoshen Wang; Tingting Xu; Chaosu Hu; Hongmei Ying
Journal:  Cancer Manag Res       Date:  2018-11-21       Impact factor: 3.989

6.  Evaluation of Prognostic Factors for the Parotid Cancer Treated With Surgery and Postoperative Radiotherapy.

Authors:  Yong-Hyub Kim; Woong-Ki Chung; Jae-Uk Jeong; Ick Joon Cho; Mee Sun Yoon; Ju-Young Song; Taek-Keun Nam; Sung-Ja Ahn; Dong Hoon Lee; Tae Mi Yoon; Joon Kyoo Lee; Sang Chul Lim
Journal:  Clin Exp Otorhinolaryngol       Date:  2019-09-05       Impact factor: 3.372

7.  Nodal Metastases in Acinic Cell Carcinoma of the Parotid Gland.

Authors:  Stefan Grasl; Stefan Janik; Matthaeus C Grasl; Johannes Pammer; Michael Formanek; Ilan Weinreb; Bayardo Perez-Ordonez; Andrew Hope; Ali Hosni; John R de Almeida; Jon Irish; Ralph Gilbert; David P Goldstein; Boban M Erovic
Journal:  J Clin Med       Date:  2019-08-27       Impact factor: 4.241

8.  Nomogram Predicting Cancer-Specific Death in Parotid Carcinoma: a Competing Risk Analysis.

Authors:  Xiancai Li; Mingbin Hu; Weiguo Gu; Dewu Liu; Jinhong Mei; Shaoqing Chen
Journal:  Front Oncol       Date:  2021-10-13       Impact factor: 6.244

9.  Management of clinically negative neck in salivary gland cancers - elective neck dissection, irradiation, or surveillance?

Authors:  Mateusz Szewczyk; Paweł Golusiński; Jakub Pazdrowski; Piotr Pieńkowski; Wojciech J Golusiński
Journal:  Contemp Oncol (Pozn)       Date:  2019-10-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.